Treatment for hepatitis B in patients with drug resistance
Authors:
- 1 September 2016
- journal article
- review article
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 4 (18) , 334
Abstract
Persistent hepatitis B virus (HBV) infections affect about 240 million patients worldwide that are at risk of developing liver cirrhosis or hepatocellular carcinoma. HBV is a small, partially double stranded DNA virus with four overlapping genes and a unique life cycle, which involves the generation of an RNA template for replication via reverse transcription. Mutations occur frequently during chronic infection, and particular selection pressures select distinct mutants. Nucleoside and nucleotide analogues like lamivudine (LMV), entecavir (ETV), telbivudine (LdT), adefovir dipivoxil (ADV) and tenofovir (TDF) are used to achieve long-term suppression of viral replication. Importantly, these drugs have different barriers to resistance, explaining the higher incidence of treatment failure in the past due to drug resistant viral strains for the older compounds LMV, LdT and ADV. On a molecular level, drug resistant mutations usually affect the reverse transcriptase domain of the HBV polymerase protein. Secondary compensatory mutations restore the replication fitness of the mutant virus. From a clinical point of view, patients undergoing antiviral therapy require regular testing for HBV DNA (every 3–6 months). In case of insufficient viral suppression or viral breakthrough (>1 log increase in HBV DNA above nadir), strict adherence to therapy needs to be ensured. If drug resistance is suspected or even molecularly confirmed, rescue therapy strategies exist, usually switching to a noncross-resistant antiviral drug. LMV, LdT and ETV resistant HBV can be treated with TDF monotherapy, ADV resistance with ETV or TDF, and insufficient responses to TDF may require ETV either as mono- or combination therapy. Complex treatment histories with many antivirals may sometimes necessitate the combination of highly effective antivirals like ETV and TDF. Novel treatment targets such as core (capsid) inhibitors, siRNA targeting protein translation, entry inhibitors or immune modulators aim at improving the efficacy of antivirals in order to (functionally) cure hepatitis B.Keywords
This publication has 35 references indexed in Scilit:
- The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013The Lancet, 2016
- Efficacy of tenofovir-based rescue therapy in patients with lamivudine-resistant hepatitis B virus: A systematic review and meta-analysisClinics and Research in Hepatology and Gastroenterology, 2016
- Overview of hepatitis B viral replication and genetic variabilityJournal of Hepatology, 2016
- New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virusJournal of Hepatology, 2016
- From non-A, non-B hepatitis to hepatitis C virus cureJournal of Hepatology, 2015
- Assessing long-term treatment efficacy in chronic hepatitis B and C: Between evidence and common senseJournal of Hepatology, 2012
- Sustained Responses and Loss of HBsAg in HBeAg-Negative Patients With Chronic Hepatitis B Who Stop Long-Term Treatment With AdefovirGastroenterology, 2012
- Hepatitis B e antigen‐suppressing mutations enhance the replication efficiency of adefovir‐resistant hepatitis B virus strainsJournal of Viral Hepatitis, 2012
- Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort studyJournal of Hepatology, 2012
- Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis BGut, 2010